Condition

Prostate CA

ClinicalTrials.gov condition label

Clinical trials13

Recruiting9

Common interventions24

Lead sponsors shown11

Clinical trials

13 shown

Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination StudyNCT06987045 · 2026-04-04

Fezolinetant for Treating Hot Flashes in Men With Prostate CancerNCT06972875 · 2025-12-18

Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate CancerNCT06835725 · 2025-09-04

Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate CancerNCT07056790 · 2025-05-15

Ultralow Dose PET Imaging for PSMA ExpressionNCT06904313 · 2025-05-12

Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate CancerNCT06834321 · 2025-03-19

Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate CancerNCT06861192 · 2025-02-16

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate CancerNCT06631521 · 2024-10-22

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate CancerNCT06636682 · 2024-10-14

Prostate MRI Analysis by Radiologists and Artificial Intelligence - Disease Identification and Guided ManagementNCT07647445 · 2026-10-01

NOT_YET_RECRUITING

Prostate Cancer Care Disparity Analysis Project (ProGAP)NCT06612034 · 2025-03-10

Clinical Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate CancerNCT06861166 · 2025-03-10

NOT_YET_RECRUITING

Research on PSMA-Targeted Intraoperative Fluorescent Imaging AgentsNCT07101354 · 2024-06-24

Common interventions

radical prostatectomyPROCEDURE4 0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6)DRUG1 0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6)DRUG1 0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6)DRUG1 0.08mg/kg DGPR1008 Injection Dose Group 4 (n=6)DRUG1 68Ga-PSMA-CYCDRUG1 AI (Lucida Pi) interpretationDIAGNOSTIC_TEST1 Androgen deprivation treatmentDRUG1 CYCDRUG1 DarolutamideDRUG1 Dose Group 0 (n=8)DRUG1 Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapyDRUG1 FezolinetantDRUG1 FK-PC101BIOLOGICAL1 Geranium wilfordii combined with androgen deprivation treatmentDRUG1 Homoharringtonine combined with androgen deprivation therapyDRUG1 No Intervention: Observational CohortOTHER1 Piflufolastat F18DRUG1 Placebo combined with androgen deprivation therapyDRUG1 Placebo combined with androgen deprivation treatment groupDRUG1 Radiologist interpretationDIAGNOSTIC_TEST1 RelugolixDRUG1 Standard of Care (SOC)BIOLOGICAL1 Stereotactic Body Radiation Therapy (SBRT)RADIATION1

Leading sponsors

baotai Liang3 AdventHealth1 Akiva Mintz1 Ankara University1 British Columbia Cancer Agency1 Cellvax Therapeutics Inc1 First Affiliated Hospital of Fujian Medical University1 Haitao Niu, MD1 Queen Mary University of London1 University College, London1 University of Vermont1

Trial status mix

RECRUITING9

NOT_YET_RECRUITING2

COMPLETED1

UNKNOWN1

Phase mix

PHASE28

PHASE13

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.